注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
亞盛醫藥集團是一家主要從事開發癌症、乙型肝炎病毒及若干衰老相關疾病的創新微型療法的投資控股公司。該公司擁有自主研發的蛋白-蛋白相互作用靶向藥物設計平台。該公司的主要產品包括下一代激酶抑製劑HQP1351,細胞凋亡靶向藥物APG-1252、 APG2575、APG-115等。該公司於國內市場及美國等海外市場開展業務。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Hagop M. Kantarjian | - | 2023 | Member of Clinical Advisory Board |
Changqing Ye | 53 | 2019 | Independent Non-Executive Director |
Dazhong Lu | 54 | 2018 | Non-Executive Director |
Shaomeng Wang | 58 | 2017 | Co-Founder, Chief Scientific Advisor & Non-Executive Director |
Arul M. Chinnaiyan | - | - | Member of Clinical Advisory Board |
Dajun Yang | 60 | 2009 | Co-Founder, Chairman & CEO |
Allen S. Lichter | 77 | 2023 | Chairman of the Clinical Advisory Board |
Asher A. Chanan-Khan | - | 2023 | Member of Clinical Advisory Board |
Zheng Yin | 50 | 2019 | Independent Non-Executive Director |
Paul A. Bunn | 78 | - | Member of Clinical Advisory Board |
David Sidransky | 63 | 2021 | Independent Non-Executive Director |
Jedd D. Wolchok | - | 2021 | Member of Clinical Advisory Board |
Wei Ren | 43 | 2019 | Independent Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核